AVADEL PHARMACEUTICALS PLC Quarterly Operating Income (Loss) in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Avadel Pharmaceuticals Plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2011 to Q3 2024.
  • Avadel Pharmaceuticals Plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$327K, a 99.1% increase year-over-year.
  • Avadel Pharmaceuticals Plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$64M, a 52.9% increase year-over-year.
  • Avadel Pharmaceuticals Plc annual Operating Income (Loss) for 2023 was -$138M, a 39.9% decline from 2022.
  • Avadel Pharmaceuticals Plc annual Operating Income (Loss) for 2022 was -$98.6M, a 15.2% decline from 2021.
  • Avadel Pharmaceuticals Plc annual Operating Income (Loss) for 2021 was -$85.5M, a 1571% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$64M -$327K +$34.8M +99.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$98.8M -$12.7M +$36.8M +74.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$136M -$26M +$2.26M +8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$138M -$24.9M -$1.86M -8.08% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$136M -$35.1M -$18.2M -107% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$118M -$49.5M -$19.6M -65.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$98.2M -$28.3M +$328K +1.15% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$98.6M -$23M +$98K +0.42% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$98.7M -$17M +$8.7M +33.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$107M -$29.9M -$8M -36.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$99.4M -$28.6M -$13.8M -93.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$85.5M -$23.1M -$8.88M -62.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$76.7M -$25.7M -$12M -87.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$64.7M -$21.9M -$62.2M -154% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$2.5M -$14.8M -$8.31M -128% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $5.82M -$14.3M -$6.91M -94.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 $12.7M -$13.7M -$9.55M -230% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $22.3M $40.3M +$44.7M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$22.4M -$6.5M +$1.67M +20.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$24.1M -$7.35M +$68.1M +90.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-16
Q3 2019 -$92.2M -$4.15M +$9.95M +70.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$102M -$4.45M -$1.67M -59.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$100M -$8.17M +$4.46M +35.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$105M -$75.4M -$71.3M -1749% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-09
Q3 2018 -$33.6M -$14.1M -$40.2M -154% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $6.63M -$2.79M -$36.9M -108% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $43.5M -$12.6M -$46M -138% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $89.5M -$4.08M -$21.1M -124% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-16
Q3 2017 $111M $26.1M +$42.3M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $68.3M $34.1M +$45.7M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $22.7M $33.3M +$27.6M +485% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 -$4.97M $17.1M -$60.3M -78% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-15
Q3 2016 $55.4M -$16.2M -$1.7M -11.8% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $57.1M -$11.5M -$9.17M -387% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $66.2M $5.7M -$4.51M -44.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $70.8M $77.4M +$111M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-16
Q3 2015 -$39.8M -$14.5M +$2.33M +13.9% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$42.2M -$2.37M +$17M +87.8% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$59.2M $10.2M +$34.4M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$93.7M -$33.2M -$30.5M -1142% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-28
Q3 2014 -$63.1M -$16.8M -$10M -147% Jul 1, 2014 Sep 30, 2014 6-K 2014-11-17
Q2 2014 -$53.1M -$19.4M +$15M +43.6% Apr 1, 2014 Jun 30, 2014 6-K 2015-12-31
Q1 2014 -$68.1M -$24.2M -$14.4M -146% Jan 1, 2014 Mar 31, 2014 6-K 2015-07-10
Q4 2013 -$53.7M -$2.67M -$5.65M -190% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$48M -$6.8M -$286K -4.39% Jul 1, 2013 Sep 30, 2013 6-K 2014-11-17
Q2 2013 -$47.8M -$34.4M -$28M -443% Apr 1, 2013 Jun 30, 2013 6-K 2014-08-08
Q1 2013 -$19.7M -$9.85M -$9.81M -21315% Jan 1, 2013 Mar 31, 2013 6-K 2014-07-08
Q4 2012 -$9.91M $2.98M Oct 1, 2012 Dec 31, 2012 20-F/A 2015-10-01
Q3 2012 -$6.52M Jul 1, 2012 Sep 30, 2012 6-K 2014-01-15
Q2 2012 -$6.33M -$2.68M -73.2% Apr 1, 2012 Jun 30, 2012 6-K 2013-12-06
Q1 2012 -$46K +$4.85M +99.1% Jan 1, 2012 Mar 31, 2012 6-K 2012-09-13
Q2 2011 -$3.66M Apr 1, 2011 Jun 30, 2011 6-K 2012-12-14
Q1 2011 -$4.89M Jan 1, 2011 Mar 31, 2011 6-K 2012-09-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.